Skip to main content
. Author manuscript; available in PMC: 2017 Jun 15.
Published in final edited form as: Cancer Res. 2016 Apr 12;76(12):3473–3483. doi: 10.1158/0008-5472.CAN-15-1742

Figure 5. Potent in vivo antitumor immunity of iPSC-derived less-differentiated CD8+ T cells.

Figure 5

(A and B) Tumor growth curves (A) and survival curves (B) in C57BL/6 mice bearing B16 melanomas established for 7 days in different treatment groups. Sp-T: Pmel-1 splenic CD8+ T cells. iPSC-T: Pmel-1 iPSC-derived CD8+ T cells. Tumor volume results are the mean of measurements from 5 mice per group. (* = P < 0.0001 using log-rank (Mantel-Cox) test.) Data shown are representative of 2 independent experiments.